Ignite Creation Date:
2024-05-06 @ 12:51 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03861793
Status:
COMPLETED
Last Update Posted:
2024-03-05
First Post:
2019-02-25
Brief Title:
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 Nemvaleukin Alfa as a Single Agent and in Combination With Anti-PD-1 Antibody Pembrolizumab in Subjects With Select Advanced or Metastatic Solid Tumors ARTISTRY-2
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Organization Data
Organization:
Mural Oncology Inc
Class:
INDUSTRY
Study ID:
ALKS 4230-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Mural Oncology Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None